Percutaneous Nephrolithotomy (PCNL) in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Renal calculi ≥ 20 mm in any calyx (EAU Grade A indication)

• Complete or partial staghorn calculi (struvite, cystine, calcium oxalate)

• Lower-pole stones ≥ 15 mm where ESWL clearance is anatomically unfavourable (infundibulopelvic angle < 70°, infundibular length > 30 mm)

• Stones refractory to or unsuitable for Extracorporeal Shock Wave Lithotripsy (ESWL) or Retrograde Intrarenal Surgery (RIRS/URS)

• Calyceal diverticulum stones with narrow neck precluding retrograde access

• Patients with ureteropelvic junction obstruction (UPJO) coexisting with calculi, requiring simultaneous endopyelotomy

• Patients with prior failed ureteroscopy or ESWL (residual stone burden > 10 mm)

• Children with large renal stones (paediatric Mini-PCNL via 14–16 Fr tract)

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Non-contrast CT KUB (NCCT) — mandatory for stone burden volumetric assessment, Hounsfield Unit (HU) density, and 3D collecting system mapping

• Intravenous Pyelogram (IVP) or CT Urogram — evaluating pelvicalyceal anatomy and ipsilateral drainage

• Urine culture and sensitivity — mandatory; active UTI must be treated before elective PCNL

• Serum metabolic panel: creatinine, eGFR, electrolytes, uric acid, calcium, phosphate, parathyroid hormone (PTH) if hypercalcaemia suspected

• Complete Blood Count (CBC), PT/INR, aPTT — coagulation assessment

• Renal ultrasound — baseline hydronephrosis grading

• DMSA or MAG3 nuclear renal scan — split renal function evaluation in solitary kidney or bilateral disease

• ECG and anaesthesiology fitness assessment (ASA classification)

• 24-hour urine stone risk profile (oxalate, citrate, uric acid, calcium) — metabolic workup for recurrence prevention

• ABSOLUTE CONTRAINDICATIONS:

• Untreated coagulopathy or active anticoagulation not reversible pre-operatively

• Active, uncontrolled systemic infection / urosepsis

• Uncorrectable bleeding diathesis (haemophilia without factor cover)

• Pregnancy (relative; radiation exposure risk)

• RELATIVE CONTRAINDICATIONS / INCREASED RISK FACTORS:

• Solitary functioning kidney (proceed with heightened haemostatic precautions)

• Morbid obesity (BMI > 45) — positioning and access challenges; prone position anaesthetic risk

• Severe cardiopulmonary compromise (ASA IV) — requires MDT anaesthetic pre-optimisation

• Horseshoe or ectopic kidney — modified approach by high-volume surgeon mandatory

• Prior ipsilateral open renal surgery — perinephric scarring increases haemorrhage and organ injury risk

STANDARD PCNL (24–30 Fr Amplatz Sheath) The classic approach uses a 24–30 French Amplatz working sheath. A Chiba needle is advanced into the target calyx under combined fluoroscopic and ultrasound guidance; a safety guidewire is placed, and serial fascial dilation (balloon dilator or Amplatz dilators) creates the nephrostomy tract. A rigid nephroscope (Karl Storz or Olympus platform) is introduced, and the calculus is fragmented using a Holmium:YAG laser (pulse energy 0.5–3.0 J; frequency 5–20 Hz) or a dual-energy probe (EMS LithoClast Trilogy). Fragments are extracted via a stone forceps or Ellik evacuator. A 16–18 Fr nephrostomy tube is placed at closure. Indicated for: stones > 30 mm, complex staghorn calculi, and surgeons requiring maximal working space.

MINI-PCNL (14–20 Fr) Mini-PCNL uses a 14–20 French working sheath and a smaller-calibre nephroscope, reducing parenchymal trauma and bleeding risk. Stone-free rates for stones 20–40 mm are comparable to standard PCNL (88–93%) with significantly lower transfusion rates (< 2% vs. 5–8% standard). Suitable for most adult patients with stones 15–40 mm; the preferred approach in many high-volume Indian centres.

ULTRA-MINI PCNL (11–13 Fr) AND MICRO-PCNL (4.8 Fr) Ultra-mini PCNL (11–13 Fr) employs a suction sheath that evacuates stone dust simultaneously, dramatically shortening operative time. Micro-PCNL (Miniperc needle — 4.8 Fr) is designed for small, isolated calyceal stones in paediatric patients or adults requiring access to difficult calyces. Both techniques allow tubeless or totally nephrostomy-tube-free exit strategies, reducing postoperative pain and enabling same-day mobilisation.

TUBELESS AND TOTALLY TUBELESS PCNL In carefully selected patients with low stone burden, no significant bleeding, and confirmed complete stone clearance, a ureteral Double-J (DJ) stent alone (tubeless) or no internal/external drainage device (totally tubeless) is placed. Meta-analysis data demonstrate faster discharge (mean 1.8 vs. 3.5 days) and reduced analgesic requirements with no increase in complication rates in low-risk cases.

ROBOTIC-ASSISTED AND IMAGE-GUIDED PCNL Emerging platforms such as the Monarch robotic flexible ureteroscope system and CT-fluoroscopy fusion navigation (e.g., Uro-CT guidance suites available at select JCI centres in India and Dubai) are improving calyceal puncture accuracy, especially for posterior upper-pole calyces adjacent to the pleura. Robotic guidance reduces radiation exposure (up to 40% dose reduction) and puncture-related complications.

SIMULTANEOUS BILATERAL PCNL (BCPCNL) For bilateral staghorn or large bilateral renal stones, simultaneous bilateral PCNL in the prone split-leg position is offered at high-volume centres in India, reducing total anaesthetic exposure and patient travel time. Patient selection requires meticulous pre-operative renal function and coagulation assessment.

ADJUNCT MEDICAL EXPULSIVE THERAPY POST-PCNL Alpha-1 adrenergic blockers (tamsulosin 0.4 mg OD) are routinely prescribed post-PCNL to facilitate spontaneous passage of residual fragments ≤ 4 mm. Potassium citrate or thiazide diuretics are initiated at discharge based on 24-hour urine metabolic profiling for long-term stone recurrence prevention.

PHASE 1 — PRE-OPERATIVE EVALUATION (Days -14 to -2 Before Surgery) Step 1 | Remote Case Review: Patient submits NCCT KUB, urine culture report, creatinine, and CBC to GAF Healthcare. A GAF-affiliated urologist provides a written opinion and operative plan within 48 hours. Step 2 | Travel & Visa Arrangement: GAF Healthcare initiates the e-Medical Visa application for India (or UAE entry visa facilitation). Flight and airport transfer are pre-arranged. Step 3 | Hospital Admission Workup (Day -1): Patient arrives at the hospital. Anaesthesiology assessment (ASA grading, airway evaluation, echocardiography if cardiac history). Repeat urine culture to confirm sterility. Coagulation panel. Any anti-platelet or anticoagulant medications (aspirin, warfarin, novel oral anticoagulants) are held per protocol — typically 5–7 days pre-operatively. Step 4 | Anaesthetic Counselling: PCNL is performed under general anaesthesia (GA) or spinal anaesthesia (SA). SA is preferred in moderate-risk cardiopulmonary patients; GA allows prone positioning without patient discomfort.

PHASE 2 — THE PROCEDURE (Day 0; Operative Duration: 60–120 minutes) Step 5 | Positioning: Patient is positioned prone (standard) or supine/flank (modified Valdivia position for obese or high-risk patients; allows simultaneous retrograde ureteral access). Step 6 | Fluoroscopic + Ultrasound Guided Puncture: Target calyx (usually posterior lower-pole or upper-pole based on stone location) is punctured under real-time dual-guidance. Radiation dose is minimised using pulsed fluoroscopy. Step 7 | Tract Dilation and Nephroscopy: Serial dilation is performed. A 14–30 Fr Amplatz sheath is placed. A 0° or 12° rigid nephroscope is inserted; flexible nephroscopy is used to access non-punctured calyces. Step 8 | Lithotripsy and Extraction: Holmium:YAG laser (Moses Technology pulse modulation available at premium centres for superior stone dustification) or ultrasonic/pneumatic probe fragments the calculus. Stone dust and fragments are evacuated via the working sheath or suction. Step 9 | Fluoroscopic Clearance Check: A final fluoroscopic sweep confirms no opacified residual fragments > 4 mm. A flexible nephroscope sweep inspects all accessible calyces. Step 10 | Closure and Drainage: A 14–18 Fr nephrostomy tube is placed (or a DJ stent in tubeless cases). The wound is closed with a single absorbable suture and dressed.

PHASE 3 — IN-HOSPITAL RECOVERY (Days 1–4) Day 1 Post-Op: Patient is ambulatory within 6–8 hours. Nephrostomy tube output (colour, volume) is monitored. IV antibiotics (ceftriaxone or piperacillin-tazobactam) are continued. Haematocrit is checked at 6 hours. Day 2 Post-Op: Nephrostomy tube is clamped for a 2–4 hour trial to assess for fever, flank pain, or elevated drainage volume. If no issues, nephrostomy tube is removed (in tubeless cases: no tube was placed; DJ stent confirmation by KUB X-ray). Day 3 Post-Op: Plain X-ray KUB or low-dose CT KUB confirms stone-free status. Serum creatinine rechecked. Day 4–5 Post-Op: Discharge. Patient is given oral analgesics (NSAIDs + paracetamol), alpha-blocker (tamsulosin), oral antibiotics (based on pre-op culture sensitivity), and a follow-up instruction sheet.

PHASE 4 — POST-DISCHARGE RECOVERY (Week 1–2 In-Country) Week 1: Rest at hotel/serviced apartment arranged by GAF Healthcare. Light ambulation encouraged. No lifting > 5 kg. Adequate hydration (> 2.5 litres/day urine output target). GAF concierge nurse available for wound check and stent-related symptom triage. Week 2 (Days 10–14): Follow-up outpatient appointment. DJ stent removal via flexible cystoscopy under local anaesthesia (if DJ stent was placed — a 10-minute outpatient procedure). Final ultrasound or X-ray to confirm no hydronephrosis or residual fragments. FIT-TO-FLY: The patient is cleared for long-haul international flight at Day 10–14 post-operatively, once the nephrostomy tube is removed, stent is removed (if applicable), there is no active haematuria, creatinine is stable, and no signs of infection are present.

PHASE 5 — LONG-TERM FOLLOW-UP (Managed Remotely) 1 Month: Urine culture, serum metabolic panel. Telemedicine consultation with the operating surgeon via GAF Healthcare's platform. 3 Months: NCCT KUB to assess for residual fragments and verify collecting system drainage. 6 Months and Annually: 24-hour urine stone risk profile. Medical therapy adjustment (citrate, thiazide, allopurinol) to reduce recurrence risk from approximately 50% (untreated) to < 15% (treated).